Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 5/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6408993 | 0.99 | FAAH (0.46) | FAAHLMNANPC1RAB9AALDH1A1 | |
| SCHEMBL6411965 | 0.90 | CCR5 (0.42) | LMNAALDH1A1CCR5OPRM1 | |
| SCHEMBL6410575 | 0.90 | ALDH1A1 (0.48) | FAAHLMNAALDH1A1CCR5KMT2A | |
| SCHEMBL6411240 | 0.89 | ALDH1A1 (0.45) | LMNAALDH1A1CCR5KMT2A | |
| Hydrochloric Acid SCHEMBL6414721 | 0.89 | ALDH1A1 (0.47) | FAAHLMNAALDH1A1CCR5KMT2A | |
| Hydrochloric Acid SCHEMBL6408463 | 0.89 | CCR5 (0.41) | LMNAALDH1A1CCR5OPRM1 | |
| SCHEMBL6408956 | 0.89 | FAAH (0.44) | FAAHLMNACCR5KMT2A | |
| SCHEMBL6412966 | 0.88 | CCR8 (0.51) | CCR5KMT2A | |
| SCHEMBL6416242 | 0.88 | CCR5 (0.46) | FAAHLMNANPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6415274 | 0.88 | FAAH (0.43) | FAAHLMNACCR5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | FAAH 2623/4885LMNA 3107/4885NPC1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.